418 related articles for article (PubMed ID: 29093509)
41. Dysbiosis in gastrointestinal disorders.
Chang C; Lin H
Best Pract Res Clin Gastroenterol; 2016 Feb; 30(1):3-15. PubMed ID: 27048892
[TBL] [Abstract][Full Text] [Related]
42. Gut Microbiota-Host Interactions in Inborn Errors of Immunity.
Castagnoli R; Pala F; Bosticardo M; Licari A; Delmonte OM; Villa A; Marseglia GL; Notarangelo LD
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572538
[TBL] [Abstract][Full Text] [Related]
43. Gut microbial metabolism and colon cancer: can manipulations of the microbiota be useful in the management of gastrointestinal health?
Belcheva A; Irrazabal T; Martin A
Bioessays; 2015 Apr; 37(4):403-12. PubMed ID: 25601287
[TBL] [Abstract][Full Text] [Related]
44. Flavonoids and the gastrointestinal tract: Local and systemic effects.
Oteiza PI; Fraga CG; Mills DA; Taft DH
Mol Aspects Med; 2018 Jun; 61():41-49. PubMed ID: 29317252
[TBL] [Abstract][Full Text] [Related]
45. Emerging pathogenic links between microbiota and the gut-lung axis.
Budden KF; Gellatly SL; Wood DL; Cooper MA; Morrison M; Hugenholtz P; Hansbro PM
Nat Rev Microbiol; 2017 Jan; 15(1):55-63. PubMed ID: 27694885
[TBL] [Abstract][Full Text] [Related]
46. Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre.
Thoua NM; Bunce C; Brough G; Forbes A; Emmanuel AV; Denton CP
Rheumatology (Oxford); 2010 Sep; 49(9):1770-5. PubMed ID: 20530510
[TBL] [Abstract][Full Text] [Related]
47. Construct validity of the Patient-Reported Outcomes Measurement Information System gastrointestinal symptom scales in systemic sclerosis.
Nagaraja V; Hays RD; Khanna PP; Spiegel BM; Chang L; Melmed GY; Bolus R; Khanna D
Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1725-30. PubMed ID: 24692332
[TBL] [Abstract][Full Text] [Related]
48. Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/ distention.
Frech TM; Khanna D; Maranian P; Frech EJ; Sawitzke AD; Murtaugh MA
Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S22-5. PubMed ID: 21586214
[TBL] [Abstract][Full Text] [Related]
49. Potential Role of the Gut Microbiome in ALS: A Systematic Review.
Wright ML; Fournier C; Houser MC; Tansey M; Glass J; Hertzberg VS
Biol Res Nurs; 2018 Oct; 20(5):513-521. PubMed ID: 29925252
[TBL] [Abstract][Full Text] [Related]
50. Saturated long-chain fatty acid-producing bacteria contribute to enhanced colonic motility in rats.
Zhao L; Huang Y; Lu L; Yang W; Huang T; Lin Z; Lin C; Kwan H; Wong HLX; Chen Y; Sun S; Xie X; Fang X; Yang H; Wang J; Zhu L; Bian Z
Microbiome; 2018 Jun; 6(1):107. PubMed ID: 29903041
[TBL] [Abstract][Full Text] [Related]
51. Gastrointestinal manifestations in Hungarian scleroderma patients.
Szamosi S; Szekanecz Z; Szucs G
Rheumatol Int; 2006 Oct; 26(12):1120-4. PubMed ID: 16770615
[TBL] [Abstract][Full Text] [Related]
52. Intestinal Pathology and Gut Microbiota Alterations in a Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Mouse Model of Parkinson's Disease.
Lai F; Jiang R; Xie W; Liu X; Tang Y; Xiao H; Gao J; Jia Y; Bai Q
Neurochem Res; 2018 Oct; 43(10):1986-1999. PubMed ID: 30171422
[TBL] [Abstract][Full Text] [Related]
53. Gastrointestinal microbial populations can distinguish pediatric and adolescent Acute Lymphoblastic Leukemia (ALL) at the time of disease diagnosis.
Rajagopala SV; Yooseph S; Harkins DM; Moncera KJ; Zabokrtsky KB; Torralba MG; Tovchigrechko A; Highlander SK; Pieper R; Sender L; Nelson KE
BMC Genomics; 2016 Aug; 17(1):635. PubMed ID: 27527070
[TBL] [Abstract][Full Text] [Related]
54. Influence of proton pump inhibitor or rebamipide use on gut microbiota of rheumatoid arthritis patients.
Kim JW; Jeong Y; Park SJ; Jin H; Lee J; Ju JH; Ji GE; Park SH
Rheumatology (Oxford); 2021 Feb; 60(2):708-716. PubMed ID: 32789440
[TBL] [Abstract][Full Text] [Related]
55. Effect of gastrointestinal manifestations on quality of life in 87 consecutive patients with systemic sclerosis.
Omair MA; Lee P
J Rheumatol; 2012 May; 39(5):992-6. PubMed ID: 22467930
[TBL] [Abstract][Full Text] [Related]
56. Gut microbiota and the development of pediatric diseases.
Lu CY; Ni YH
J Gastroenterol; 2015 Jul; 50(7):720-6. PubMed ID: 25917564
[TBL] [Abstract][Full Text] [Related]
57. Gut Microbiota in Human Systemic Lupus Erythematosus and a Mouse Model of Lupus.
Luo XM; Edwards MR; Mu Q; Yu Y; Vieson MD; Reilly CM; Ahmed SA; Bankole AA
Appl Environ Microbiol; 2018 Feb; 84(4):. PubMed ID: 29196292
[TBL] [Abstract][Full Text] [Related]
58. Gastrointestinal involvement in systemic sclerosis: An updated review.
Nassar M; Ghernautan V; Nso N; Nyabera A; Castillo FC; Tu W; Medina L; Ciobanu C; Alfishawy M; Rizzo V; Eskaros S; Mahdi M; Khalifa M; El-Kassas M
Medicine (Baltimore); 2022 Nov; 101(45):e31780. PubMed ID: 36397401
[TBL] [Abstract][Full Text] [Related]
59. Disorder of gut amino acids metabolism during CKD progression is related with gut microbiota dysbiosis and metagenome change.
Liu Y; Li J; Yu J; Wang Y; Lu J; Shang EX; Zhu Z; Guo J; Duan J
J Pharm Biomed Anal; 2018 Feb; 149():425-435. PubMed ID: 29169110
[TBL] [Abstract][Full Text] [Related]
60. The potential pathogenic role of gut microbiota in rheumatic diseases: a human-centred narrative review.
Bixio R; Bertelle D; Bertoldo E; Morciano A; Rossini M
Intern Emerg Med; 2024 Jun; 19(4):891-900. PubMed ID: 38141117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
